Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending dose study of subcutaneous RO7049665 in healthy male volunteers
NL-OMON47456Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in autoimmune disease comparing RO7049665 single ascending dose with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2017; status: active, not recruiting.
02
Drugs
melredableukin alfa
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON47456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47456.